KLAR Share Price Performance
SEK 0.83
-0.42 (-33.86%)
Price SEK 0.83
Share Pricen/a
Klaria Pharma Holding AB (publ.) Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
KLAR Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Klaria Pharma Holding AB (publ.) Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.16
- 100.00%
- -432.80%
- 0%
About KLAR
- Founded
- 2014
- Employees
- 4
- CEO
- WebsiteView website
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; and Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. The company is also involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquartered in Uppsala, Sweden.
